Insight Series

Risk Assessment for Gene Editing Technologies and Outcomes

October 18, 2023 | 11:00 AM CT

Emerging technologies seek to avoid risks associated with genomic cleavage/repair through single base editing. Discussions will focus on state-of-the-art technologies and assays for integration site profiling, clonality, and oncogenesis. Another topic to be discussed is the translational and regulatory utility of these data for supporting ongoing and future human gene therapy studies.


  • Moderators: Andrew Wilber, PhD - Southern Illinois University School of Medicine, and Kshitiz Singh, MBBS, MMST - Queen's University

  • Shengdar Tsai, PhD - St. Jude Children's Hospital
    Genomic analysis of genome editing outcomes and consequences for the human genome

  • Doug Smith, PhD - SeQureDx
    Democratizing Gene Editor Safety Through Variant Aware Off-Target Profiling

  • Lauren Gauthier - Takeda Therapeutics
    Safety of cell therapy products – cytokine independent growth assays for tumorigenicity

Watch on demand

More ASGCT Insights

Register for more sessions during ASGCT Insights Week, Oct. 16-20. Members and registrants can watch on demand!


Register for the ASGCT Policy Summit

September 23-24, 2024 | Washington, D.C.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.